Press Release Immunomic Therapeutics, Inc. 9290 Gaither Road Gaithersburg, MD 20877
March 15, 2008 Ph: 240-731-5232 Fax: 240-597-4061 info@immunomictherapeutics.com www.immunomix.com
FOR IMMEDIATE RELEASE: March 15, 2008 (Gaithersburg, MD)
Immunomic Therapeutics Selected to Present at Two Venture Fairs Gaithersburg, MD, March 15, 2008 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomix.com) announced today that the Company has been selected to present at the company to investors at the 3 rivers venture fair (www.3rvf.com) in Pittsburgh April 16-17 and at the Philadelphia Angel Venture Fair on April 22 (www.angelventurefair.com). To be selected, ITI competed against over 120 other entrants for each venture fair. Entrants were chosen based on elements of the business plan submitted to the judging committees of each event. ITI is one of approximately 20 companies presenting at each event and is the only company that has been invited back from 2007 for the Angel Venture Fair. Dr. Bill Hearl, President & CEO of Immunomic Therapeutics said, “I am looking forward to the opportunity to present ITI to the investment community and to share our progress over the last few months. We are seeking a combination of angel and venture capital in 2008 and we think these two forums will give us a great start on that process. We are very grateful to the selection committees of both events and we are excited to be part of these fantastic programs.” About the 3 Rivers Venture Fair The 3 Rivers Venture Fair is presented by the Pittsburgh Venture Capital Association and is managed by the organization’s executive director, co-chairs and planning committees. It is a cooperative effort among many organizations and volunteers; the event is being held at The Lexus Club at Pittsburgh’s PNC Park. About the Angel Venture Fair The Angel Venture Fair, one of the few events organized by and exclusively for private investors, is brought to you by the Private Investors Forum (PIF), a non-profit organization of accredited private investors dedicated to providing education and stimulating investment in the Greater Philadelphia Region, including New Jersey, Delaware and Maryland. The 2008 event will be held in Philadelphia on April 21-22; visit the website at www.angelventurefair.com. About Immunomic Therapeutics Immunomic Therapeutics, Inc. (“ITI”) is a privately held biotechnology company headquartered in Gaithersburg, Maryland that is commercializing DNA vaccines that are important to human health. ITI’s vaccines utilize its proprietary LAMP Technology and have been shown to enhance the immune response in human clinical studies. LAMP vaccines are currently in or preparing for clinical studies for cancer (AML and prostate cancer), therapeutic HIV, allergy and influenza. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com. This press release may contain forward looking statements regarding, among other matters, the Company's future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI’s technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company's competitors and other competitive factors. ____________________________ CONTACT: Immunomic Therapeutics, Inc. Bill Hearl, Ph.D., President & CEO 240-731-5232 info@immunomictherapeutics.com Iti_pr_11